Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corp was incorporated in 1989 by Paul Averback, a pathologist who previously founded Diagnostic Cytology Laboratories. The company is headquartered in Havre de Grace, Maryland, and has focused on developing therapeutic candidates targeting age-related conditions, including benign prostatic hyperplasia (BPH) and Alzheimer's disease. Nymox's primary product candidate is NX-1207, a drug administered via intraprostatic injection for BPH. The company has also explored NX-210 for Alzheimer's disease, though development has lagged behind NX-1207. The pipeline is exclusively pharmaceutical, with no disclosed venture capital or co-investment strategy. Operations are primarily US-based, with a Danish subsidiary (Nymox Pharma A/S) that has historically supported European clinical trials. The firm is publicly traded on the NASDAQ under the ticker NYMX. It has a small team of fewer than ten full-time employees, as disclosed in SEC filings. Team size and deployment are constrained by the firm's market capitalization and cash position, which have fluctuated over the years. The company maintains no philanthropic foundations or adjacent investment vehicles. A structural differentiator is Nymox's razor-thin operation; the company has spent decades developing a single drug candidate without diversifying into other therapeutic areas or diagnostic tools. That narrow focus has created a high-conviction, high-risk profile that differs from larger pharmaceutical companies and biotech asset managers alike.